Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017033208) IMPLANTABLE NALTREXONE TABLETS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

We claim:

1. A naltrexone implantable tablet composition comprising naltrexone in an amount of 500 to 2000 mg, wherein, the composition is devoid of Magnesium salts and corticosteroids.

2. The Naltrexone implantable tablet composition according to claim 1, wherein, the composition comprises Naltrexone embedded in biodegradable polymers/polyesters along with Eudragit copolymer and a lubricant to provide a controlled amount of the active over a period of 3 months or more.

3. The Naltrexone implantable tablet composition according to claim 1, wherein, the biodegradable polymers/polyesters are selected from DL-lactides and/or glycolides.

4. The Naltrexone implantable tablet composition according to claim 3, wherein, the polymer is DL-Lactide/Glycolide Co-Polymer of variable compositions selected from the group consisting of 50:50, 65:35, 75:25, 85: 15, 5:95,15:85 and 25:75.

5. The Naltrexone implantable tablet composition according to claim 1, wherein, the Eudragit copolymer is selected from the group consisting of Eudragit® NE 30 D, Eudragit ® NE 40 D, Eudragit ® NM 30 D Eudragit ® RSI 00 and Eudragit ® RL 100.

6. The Naltrexone implantable tablet composition according to claim 1, wherein, the lubricant is selected from stearic acid, glyceryl monostearate or combination thereof.

7. The Naltrexone implantable tablet composition according to claim 1, wherein, the strength of the Naltrexone is about 765mg or about 903 mg.

8. The Naltrexone implantable tablet composition according to claim 1, wherein, the implant is provided as a one tablet or two tablet systems.

9. The Naltrexone implantable tablet composition according to claim 1, wherein, the corticosteroid is selected from triamcinolone, prednisolone, hydrocortisone, and salts thereof.

10. The Naltrexone implantable tablet composition according to claim 1, wherein, the composition releases a dose of about 0.9 mg/day to 15 mg/day in vitro to give a targeted effective dose of about 1 ng /ml to 5.2 ng/ml per day in vivo over a period of 3 months or more.

11. The Naltrexone implantable tablet composition according to claim 1, comprising dimensions of about 2 mm to 12 mm diameter and 0.5 cm to 3 cm length.

12. The Naltrexone implantable tablet composition according to claim 11, wherein, the tablet comprising 8.5mm-11.2mm diameter and about 9mm - 11.4mm in length.

13. The Naltrexone implantable tablet composition according to claim 1, wherein, the composition optionally comprises additional active agent selected from an anti-biotic agent such as cephalosporin or an anti-inflammatory agent, antihistamine such as a corticosteroid which include but are not limited to Triamcinolone, dexamethasone, betamethasone, embedded in biodegradable polymers /polyesters along with Eudragit and a lubricant.

14. A method of sterilization of the naltrexone implantable tablet composition so as to reduce the post-sterilization noroxymorphone in the composition which method comprises subjecting the Naltrexone implants to gamma irradiation at intensity of 8-25 kGy so as to maintain the sterility of the product.

15. The method as recited in claim 14, wherein, the gamma irradiation at intensity of 8-12 kGy.

16. A method of controlling the weight loss and lethargy in a subject undergoing a treatment for opiate and alcohol dependency while maintaining the effective daily dose of naltrexone in the blood which method comprises implanting the naltrexone implantable tablet comprising naltrexone in an amount of 500 to 2000 mg, embedded in biodegradable polymers /polyesters along with Eudragit and a lubricant according to any one of the preceding claims.